Australia markets open in 7 hours 10 minutes
  • ALL ORDS

    7,624.30
    +23.80 (+0.31%)
     
  • AUD/USD

    0.7487
    -0.0064 (-0.85%)
     
  • ASX 200

    7,368.90
    +9.90 (+0.13%)
     
  • OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD

    1,763.90
    -10.90 (-0.61%)
     
  • BTC-AUD

    46,136.55
    -2,192.23 (-4.54%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     

AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
  • Oops!
    Something went wrong.
    Please try again later.

DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, AzurRx President, CEO and Chairman, will present at Investor Summit Group’s Q2 Virtual Investor Summit taking place May 17-18, 2021.

During his live virtual presentation on Monday, May 17, 2021 at 9:30 a.m. EDT, Mr. Sapirstein will provide an overview of AzurRx’s business and clinical development programs and discuss anticipated 2021 and early 2022 milestones. Additionally, Mr. Sapirstein and members of the AzurRx management team will be participating in virtual one-on-one meetings with registered investors.

Details of the presentation are as follows:

Event:

Investor Summit Group’s Q2 Virtual Summit

Date:

Monday, May 17, 2021

Time:

9:30 a.m., EDT

Registration:
Presentation:

https://investorsummitgroup.com/register/
https://zoom.us/webinar/register/WN_GvA0wYzFTm6gUl0u2xZSqg

About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit www.azurrx.com.

Forward-Looking Statement
This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; and the impact of the coronavirus (COVID-19) pandemic on the Company’s operations and current and planned clinical trials, including potential delays in clinical trial recruitment and participation. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:
AzurRx BioPharma, Inc.
1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445
Phone: (646) 699-7855
info@azurrx.com

Media contact:
Tiberend Strategic Advisors, Inc.
Johanna Bennett/Ingrid Mezo
(212) 375-2665/(646) 604-5150
jbennett@tiberend.com/imezo@tiberend.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting